Piper Sandler Rates Regeneron (REGN) Overweight on Oncology Growth

One of the event’s main themes revolved astir optimism astir BCMA T-cell engagers transitioning into second-line attraction with MAJESTEC-3 results. Leading experts claimed they were not disquieted astir sequencing CAR-T therapy pursuing BCMA T-cell engagers.

Meanwhile, Cantor Fitzgerald maintained its Overweight standing and $800 terms people for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) connected April 8. The steadfast predicted that near-term fianlimab information volition proceed to predominate first-quarter 2026 findings.

Cantor Fitzgerald isn’t expecting information earlier the Q1 2026 net call. For the quarter, the steadfast expects a lower-impact print, led by a broadly in-line and well-anticipated Eylea HD effect and a insignificant shortfall for Dupixent successful what it calls the notoriously hard archetypal quarter.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is simply a salient biopharmaceutical institution that discovers, develops, and commercializes medicines for a assortment of diseases, including cancer, oculus disorders, and allergies.

While we admit the imaginable of REGN arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and 15 Stocks That Will Make You Rich successful 10 Years 

Disclosure: None. Follow Insider Monkey connected Google News.